Literature DB >> 3137602

Effects of nootropic drugs in a scopolamine-induced amnesia model in mice.

R Verloes1, A M Scotto, J Gobert, E Wülfert.   

Abstract

Scopolamine (3 mg/kg IP) given before an acquisition trial, reduced the retention of a one-trial passive avoidance "step through" response in mice. A single administration of cholinergic agonists such as oxotremorine, BM-5, or arecoline, antagonized this amnesic effect of scopolamine. A significant anti-amnesic effect was also found with nootropic drugs such as piracetam and ucb L059, whereas ucb L060 (the enantiomer of ucb L059), oxiracetam and rolziracetam were shown to be ineffective. Moreover, ucb L059, administered twice daily for 3 days, counteracted the amnesic effects of scopolamine completely, whereas ucb L060 was again inactive. The results demonstrate that: (a) this model of impaired cognition by scopolamine is able to discriminate between closely related chemical substances and even stereoisomers; and (b) nootropic drugs, such as ucb L059, are more effective after repeated rather than after acute administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137602     DOI: 10.1007/bf00174514

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Amnesic effects of scopolamine.

Authors:  S D Glick; B Zimmerberg
Journal:  Behav Biol       Date:  1972-04

Review 2.  Behavioral methods for measuring effects of drugs on learning and memory in animals.

Authors:  G A Heise
Journal:  Med Res Rev       Date:  1984 Oct-Dec       Impact factor: 12.944

Review 3.  The cholinergic treatment strategy in aging and senile dementia.

Authors:  C A Johns; B S Greenwald; R C Mohs; K L Davis
Journal:  Psychopharmacol Bull       Date:  1983

Review 4.  The cholinergic hypothesis of geriatric memory dysfunction.

Authors:  R T Bartus; R L Dean; B Beer; A S Lippa
Journal:  Science       Date:  1982-07-30       Impact factor: 47.728

5.  Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.

Authors:  R Cumin; E F Bandle; E Gamzu; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia.

Authors:  W W Beatty; N Butters; D S Janowsky
Journal:  Behav Neural Biol       Date:  1986-03

7.  Oral physostigmine treatment of patients with Alzheimer's disease.

Authors:  R C Mohs; B M Davis; C A Johns; A A Mathé; B S Greenwald; T B Horvath; K L Davis
Journal:  Am J Psychiatry       Date:  1985-01       Impact factor: 18.112

Review 8.  Measurement of cholinergic drug effects on memory in Alzheimer's disease.

Authors:  S D Brinkman; S Gershon
Journal:  Neurobiol Aging       Date:  1983       Impact factor: 4.673

9.  Memory and cognitive function in man: does the cholinergic system have a specific role?

Authors:  D A Drachman
Journal:  Neurology       Date:  1977-08       Impact factor: 9.910

10.  Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.

Authors:  J E Christie; A Shering; J Ferguson; A I Glen
Journal:  Br J Psychiatry       Date:  1981-01       Impact factor: 9.319

View more
  11 in total

1.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

2.  Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway.

Authors:  Xiong Wang; Zhi-Hao Wang; Yuan-Yuan Wu; Hui Tang; Lu Tan; Xiang Wang; Xin-Ya Gao; Yan-Si Xiong; Dan Liu; Jian-Zhi Wang; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-10-07       Impact factor: 5.590

3.  Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer's disease.

Authors:  Mohaddeseh Sadat Alavi; Sahar Fanoudi; Mahmoud Hosseini; Hamid R Sadeghnia
Journal:  Metab Brain Dis       Date:  2022-01-31       Impact factor: 3.584

4.  Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.

Authors:  Patricia C Marisco; Fabiano B Carvalho; Michelle M Rosa; Bruna A Girardi; Jessié M Gutierres; Jeandre A S Jaques; Ana P S Salla; Víctor C Pimentel; Maria Rosa C Schetinger; Daniela B R Leal; Carlos F Mello; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

5.  Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain.

Authors:  E Abe
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes.

Authors:  Sara Sanz-Blasco; Juan C Piña-Crespo; Xiaofei Zhang; Scott R McKercher; Stuart A Lipton
Journal:  Neuroreport       Date:  2016-06-15       Impact factor: 1.837

7.  Alpha-sialyl cholesterol reverses AF64A-induced deficit in passive avoidance response and depletion of hippocampal acetylcholine in mice.

Authors:  E Abe; S Murai; Y Masuda; H Saito; T Itoh
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  The Novel Dipeptide Translocator Protein Ligand, Referred to As GD-23, Exerts Anxiolytic and Nootropic Activities.

Authors:  P Yu Povarnina; S A Yarkov; T A Gudasheva; M A Yarkova; S B Seredenin
Journal:  Acta Naturae       Date:  2015 Jul-Sep       Impact factor: 1.845

9.  Protective effect of rutin on cognitive impairment caused by phenytoin.

Authors:  Shagun Dubey; Aditya Ganeshpurkar; Divya Bansal; Nazneen Dubey
Journal:  Indian J Pharmacol       Date:  2015 Nov-Dec       Impact factor: 1.200

10.  Levetiracetam in the treatment of childhood epilepsy.

Authors:  James W Wheless
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.